JP2025525989A5 - - Google Patents
Info
- Publication number
- JP2025525989A5 JP2025525989A5 JP2025507000A JP2025507000A JP2025525989A5 JP 2025525989 A5 JP2025525989 A5 JP 2025525989A5 JP 2025507000 A JP2025507000 A JP 2025507000A JP 2025507000 A JP2025507000 A JP 2025507000A JP 2025525989 A5 JP2025525989 A5 JP 2025525989A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ngf
- seq
- use according
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22188990.0 | 2022-08-05 | ||
| EP22188990.0A EP4316505A1 (en) | 2022-08-05 | 2022-08-05 | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| PCT/EP2023/071698 WO2024028487A1 (en) | 2022-08-05 | 2023-08-04 | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025525989A JP2025525989A (ja) | 2025-08-07 |
| JP2025525989A5 true JP2025525989A5 (enExample) | 2026-04-20 |
Family
ID=82846594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025507000A Pending JP2025525989A (ja) | 2022-08-05 | 2023-08-04 | 感音性難聴の治療のためのｎｇｆの鼻腔内投与 |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP4316505A1 (enExample) |
| JP (1) | JP2025525989A (enExample) |
| CN (1) | CN119836297A (enExample) |
| AU (1) | AU2023317864A1 (enExample) |
| CA (1) | CA3263975A1 (enExample) |
| IL (1) | IL318657A (enExample) |
| WO (1) | WO2024028487A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4659759A1 (en) * | 2024-06-04 | 2025-12-10 | Dompé farmaceutici SpA | Administration of ngf for the treatment of niemann-pick type c disease |
| WO2026022244A1 (en) | 2024-07-23 | 2026-01-29 | Chiesi Farmaceutici S.P.A. | A polypeptide for use in the therapeutic management of acute ischaemic stroke |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0994188B1 (de) | 1998-10-09 | 2004-01-07 | Scil proteins GmbH | Verfahren zur Gewinnung von aktivem Beta-NGF |
| ITRM20110390A1 (it) * | 2011-07-21 | 2013-01-22 | Eramo Alessandra D | Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione. |
| CN104203264B (zh) | 2011-12-19 | 2018-08-28 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| WO2017120465A1 (en) * | 2016-01-06 | 2017-07-13 | Massachusetts Eye And Ear Infirmary | Treating cochlear synaptopathy |
| WO2018140792A2 (en) * | 2017-01-27 | 2018-08-02 | Otonomy, Inc. | Neurotrophin mutants for treating hearing loss and other otic disorders |
| EP3406259A1 (en) * | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| MA52351B1 (fr) | 2018-04-27 | 2026-04-30 | Chiesi Farmaceutici S.P.A. | Production de facteur de croissance nerveuse (ngf) et de ses mutéines |
| WO2022105847A1 (en) * | 2020-11-19 | 2022-05-27 | Staidson (Beijing) Biopharmaceuticals Co. , Ltd. | Long-acting nerve growth factor polypeptides and uses thereof |
-
2022
- 2022-08-05 EP EP22188990.0A patent/EP4316505A1/en not_active Withdrawn
-
2023
- 2023-08-04 WO PCT/EP2023/071698 patent/WO2024028487A1/en not_active Ceased
- 2023-08-04 JP JP2025507000A patent/JP2025525989A/ja active Pending
- 2023-08-04 CA CA3263975A patent/CA3263975A1/en active Pending
- 2023-08-04 EP EP23757837.2A patent/EP4565255A1/en active Pending
- 2023-08-04 IL IL318657A patent/IL318657A/en unknown
- 2023-08-04 AU AU2023317864A patent/AU2023317864A1/en active Pending
- 2023-08-04 CN CN202380063408.0A patent/CN119836297A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569391T3 (es) | Tritocualina para uso en el tratamiento de la fibrosis quística | |
| US20200384074A1 (en) | Therapeutic agent for inflammatory bowel disease | |
| JP2024503265A5 (enExample) | ||
| US10344055B2 (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| JP2023500032A5 (enExample) | ||
| CN109952103A (zh) | 用于治疗细菌感染的系统和方法 | |
| CN109996554B (zh) | 新型抗微生物和抗癌疗法 | |
| JP2025525990A5 (enExample) | ||
| CA3101006A1 (fr) | Diltiazem pour son utilisation dans le traitement des infections microbiennes | |
| JP2023520703A5 (enExample) | ||
| KR20230047396A (ko) | 리라글루티드 및 제피티닙의 항바이러스 용도 | |
| JP2025532676A5 (enExample) | ||
| RU2025104922A (ru) | Интраназальное введение ngf для лечения сенсоневральной тугоухости | |
| US7132453B2 (en) | Method of using prostacyclin to treat respiratory syncytial virus infections | |
| CN115916185B (zh) | 用于治疗腹泻的制剂和方法 | |
| JP4541642B2 (ja) | 肺感染症および肺腫瘍を治療するためのリポペプチド類およびリポプロテイン類の使用 | |
| RU2025104605A (ru) | Интраназальное введение нфгм для лечения сенсоневральной тугоухости | |
| JP4846598B2 (ja) | 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 | |
| JP2024515555A5 (enExample) | ||
| JP2024520788A5 (enExample) | ||
| JP2022176154A5 (enExample) | ||
| RU2220730C2 (ru) | Способ лечения герпетического стоматита | |
| US20240342227A1 (en) | Combination of e. faecalis and an anti-inflammatory agent and uses thereof in the prevention and/or treatment of respiratory diseases | |
| US20240116996A1 (en) | Methods and compositions for treating a coronavirus infection | |
| NL2027924B1 (en) | Antimicrobial peptide for prevention and treatment of virusinfections |